Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy.

Abstract

Evaluation of HER-2/neu status is important in the management of patients with breast carcinoma, especially in determining the possible application of trastuzumab, a humanized anti-HER-2/neu monoclonal antibody. Chromogenic in situ hybridization (CISH) detection of the HER-2/neu oncogene is a newly developed in situ hybridization method that utilizes a… (More)

Topics

Cite this paper

@article{Kumamoto2001ChromogenicIS, title={Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy.}, author={Hiroyuki Kumamoto and Hajime Sasano and Toshiyasu Taniguchi and T. Suzuki and T. Moriya and Ryo Ichinohasama}, journal={Pathology international}, year={2001}, volume={51 8}, pages={579-84} }